Minerva Neurosciences, Inc.

NERV · Nasdaq · SIC 2834: Pharmaceutical Preparations
204
SEC Filings

Business Summary

Our Clinical-Stage Programs for more information. While we are advancing plans for an additional confirmatory Phase 3 clinical trial for roluperidone for the treatment of negative symptoms in schizophrenia, which we refer to as the C19 trial, in consultation with the FDA and expect to fund such trial and our resubmission of the NDA in part with net proceeds from our October 2025 private placement, there can be no assurances that we will successfully resubmit the NDA and obtain approval for rolup...

Next Earnings

Q2 FY2026 — expected 2026-09-21

Key Facts from Earnings Calls

TypeSubjectDetailQuarter
topic_mentionNERVdiscussed_in_filing Cybersecurity
topic_mentionNERVdiscussed_in_filing Cybersecurity

Annual Reports (10-K)

FiledPeriodAccessionSourceFull Text
2026-03-112025-12-310001193125-26-101117EDGAR82K words
2025-02-252024-12-310000950170-25-026055EDGAR—
2024-02-222023-12-310000950170-24-018392EDGAR—
2023-03-082022-12-310000950170-23-006577EDGAR—
2022-03-012021-12-310001564590-22-007853EDGAR—
2021-03-082020-12-310001564590-21-011340EDGAR—
2020-03-092019-12-310001564590-20-009243EDGAR—
2019-03-122018-12-310001564590-19-007246EDGAR—
2018-03-122017-12-310001564590-18-005224EDGAR—
2017-03-132016-12-310001564590-17-004048EDGAR—

Quarterly Reports (10-Q)

FiledPeriodAccessionSourceFull Text
2025-11-052025-09-300001193125-25-265685EDGAR20K words
2025-08-142025-06-300000950170-25-108840EDGAR—
2025-05-132025-03-310000950170-25-069780EDGAR—
2024-11-052024-09-300000950170-24-121063EDGAR—
2024-08-062024-06-300000950170-24-091195EDGAR—
2024-05-012024-03-310000950170-24-050883EDGAR—
2023-11-072023-09-300000950170-23-059747EDGAR—
2023-08-012023-06-300000950170-23-036159EDGAR—
2023-05-152023-03-310000950170-23-021947EDGAR—
2022-11-092022-09-300000950170-22-023496EDGAR—
2022-08-092022-06-300000950170-22-015754EDGAR—
2022-05-042022-03-310001564590-22-017670EDGAR—

Recent Current Reports (8-K)

FiledAccessionSourceFull Text
2026-04-060001193125-26-143986EDGAR1K words
2026-04-020001193125-26-140148EDGAR—
2026-03-110001193125-26-101074EDGAR—
2026-02-030001193125-26-034538EDGAR—
2025-12-220001193125-25-328715EDGAR—
2025-11-190001193125-25-287048EDGAR—
2025-10-220001193125-25-245552EDGAR—
2025-03-190001193125-25-057901EDGAR—
2025-01-130001193125-25-005042EDGAR—
2024-12-050001193125-24-271652EDGAR—

204 total filings indexed. 172 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR

Sector Peers

SXTP — 60 DEGREES PHARMACEUTICALS, INC. ABT — ABBOTT LABORATORIES ABEO — ABEONA THERAPEUTICS INC. ABVC — ABVC BIOPHARMA, INC. ACAD — ACADIA PHARMACEUTICALS INC ACTU — ACTUATE THERAPEUTICS, INC. ADCT — ADC Therapeutics SA ADIL — ADIAL PHARMACEUTICALS, INC.

Company Identity

CIK0001598646
TickerNERV
ExchangeNasdaq
SIC2834: Pharmaceutical Preparations
IncorporatedMA

Get More Data

This is the free public profile. For structured JSON with full provenance chain, use the API:

JSON Profile Stock Quote AI Readiness Report
Origin Provenance
page leaf: 54f8ff10a237ae1ee9ecbeae25d9888bd56f715f585639ab3ec423671c84d349
parent: 234702d6c7d9730dd99d8695cebdfdf0c27b0981c9802e735a264e73aaac2c62
content hash: 51f74036eb1b0d195bc88cc43556948041193f50c8e0f4ca5378ff98c5cc66f8
signed: 2026-04-13T04:46:28.675Z
sources: 22 verified data leaves
chain: SEC.gov PEM → origin.rootz.global extraction → this page
verify: sha256(content_hash + parent + timestamp) = leaf